Association between antidepressant use and liver fibrosis in patients with type 2 diabetes: a population based study
-
Published:2023-03-11
Issue:1
Volume:15
Page:
-
ISSN:1758-5996
-
Container-title:Diabetology & Metabolic Syndrome
-
language:en
-
Short-container-title:Diabetol Metab Syndr
Author:
Shi Lin,Jia Fangyuan
Abstract
Abstract
Background
The prevalence of liver fibrosis among diabetic patients is increasing rapidly. Our study aims at exploring the relationship between antidepressant use and liver fibrosis in diabetic patients.
Methods
We conducted this cross-sectional study through the cycle of National Health and Nutrition Examination Survey (NHANES) 2017–2018. The study population were consisted of patients with type 2 diabetes and reliable vibration-controlled transient elastography (VCTE) results. The presence of liver fibrosis and steatosis were assessed by the median values of liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), respectively. Antidepressants included selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs) and serotonin antagonists and reuptake inhibitors (SARIs). Patients with evidence of viral hepatitis and significant alcohol consumption were excluded. Logistic regression analysis was performed to evaluate the association between antidepressant use and both steatosis and significant (≥ F3) liver fibrosis after adjustment for potential confounders.
Results
Our study population consisted of 340 women and 414 men, of whom 87 women(61.3%) and 55(38.7%) men received antidepressants. The most commonly used antidepressants were SSNIs(48.6%), SNRIs(22.5%) and TCAs(12.7%), followed by SARIs(10.6%) and other antidepressants(5.6%). 165 participants had significant liver fibrosis by VCTE, with a weighted overall prevalence of 24%(95% CI 19.2–29.5). In addition, 510 patients had evidence of hepatic steatosis by VCTE with a weighted overall prevalence of 75.4%(95% CI 69.2–80.7). After adjusting confounders, no significant association was observed between antidepressant use and significant liver fibrosis or cirrhosis.
Conclusions
In conclusion, in this cross-sectional study, we found that antidepressant drugs was not associated with liver fibrosis and cirrhosis in patients with type 2 diabetes in a nationwide population.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference31 articles.
1. Lloyd CE, Nouwen A, Sartorius N, Ahmed HU, Alvarez A, Bahendeka S, Basangwa D, Bobrov AE, Boden S, Bulgari V, Burti L, Chaturvedi SK, Cimino LC, Gaebel W, de Girolamo G, Gondek TM, de Braude MG, Guntupalli A, Heinze MG, Ji L, Hong X, Khan A, Kiejna A, Kokoszka A, Kamala T, Lalic NM, Lecic Tosevski D, Mankovsky B, Li M, Musau A, Mussig K, Ndetei D, Rabbani G, Srikanta SS, Starostina EG, Shevchuk M, Taj R, Vukovic O, Wolwer W, Xin Y. Prevalence and correlates of depressive disorders in people with Type 2 diabetes: results from the International Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study, a collaborative study carried out in 14 countries. Diabet Med. 2018;35(6):760–9. https://doi.org/10.1111/dme.13611. 2. Lloyd CE, Sartorius N, Ahmed HU, Alvarez A, Bahendeka S, Bobrov AE, Burti L, Chaturvedi SK, Gaebel W, de Girolamo G, Gondek TM, Guinzbourg M, Heinze MG, Khan A, Kiejna A, Kokoszka A, Kamala T, Lalic NM, Lecic-Tosevski D, Mannucci E, Mankovsky B, Mussig K, Mutiso V, Ndetei D, Nouwen A, Rabbani G, Srikanta SS, Starostina EG, Shevchuk M, Taj R, Valentini U, van Dam K, Vukovic O, Wolwer W. Factors associated with the onset of major depressive disorder in adults with type 2 diabetes living in 12 different countries: results from the INTERPRET-DD prospective study. Epidemiol Psychiatr Sci. 2020;29:e134. https://doi.org/10.1017/S2045796020000438. 3. Nouwen A, Adriaanse M, van Dam K, Iversen M, Viechtbauer W, Peyrot M, Caramlau I, Kokoszka A, Kanc K, de Groot M, Nefs G, Pouwer F. Longitudinal associations between depression and diabetes complications: a systematic review and meta-analysis. Diabet Med J Br Diabet Assoc. 2019;36(12):1562–72. https://doi.org/10.1111/dme.14054. 4. Novak M, Mucsi I, Rhee C, Streja E, Lu J, Kalantar-Zadeh K, Molnar M, Kovesdy C. Increased risk of incident chronic kidney disease, cardiovascular disease, and mortality in patients with diabetes with comorbid depression. Diabetes Care. 2016;39(11):1940–7. https://doi.org/10.2337/dc16-0048. 5. Younossi Z, Golabi P, de Avila L, Paik J, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. https://doi.org/10.1016/j.jhep.2019.06.021.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|